Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 394
- Registration Number
- NCT05151731
- Locations
- 🇺🇸
Win Retina, Arcadia, California, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retina Consultants, San Diego, Poway, California, United States
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 187
- Registration Number
- NCT05151744
- Locations
- 🇺🇸
Win Retina, Arcadia, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT05129280
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05126966
- Locations
- 🇭🇰
Hong Kong Eye Hospital; CUHK Eye Centre, Mongkok, Hong Kong
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇩🇰Sjællands Universitetshospital, Roskilde; Øjenafdelingen, Roskilde, Denmark
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT05123703
- Locations
- 🇺🇸
UC San Diego; ACTRI, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasilia, DF, Brazil
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 109
- Registration Number
- NCT05119569
- Locations
- 🇷🇸
Clinical Center Nis, NIS, Serbia
🇺🇸Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT05116202
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 259
- Registration Number
- NCT05115110
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Boston Childrens Hospital, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT05112965
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT05091424
- Locations
- 🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of